vs

Side-by-side financial comparison of AstroNova, Inc. (ALOT) and DELCATH SYSTEMS, INC. (DCTH). Click either name above to swap in a different company.

AstroNova, Inc. is the larger business by last-quarter revenue ($39.2M vs $20.7M, roughly 1.9× DELCATH SYSTEMS, INC.). AstroNova, Inc. runs the higher net margin — 1.0% vs -9.1%, a 10.1% gap on every dollar of revenue. On growth, DELCATH SYSTEMS, INC. posted the faster year-over-year revenue change (37.3% vs -3.4%). DELCATH SYSTEMS, INC. produced more free cash flow last quarter ($7.7M vs $3.3M). Over the past eight quarters, DELCATH SYSTEMS, INC.'s revenue compounded faster (157.0% CAGR vs 2.1%).

AstroNova, Inc. is a global technology firm designing, manufacturing and distributing specialty data visualization products, including high-performance label printers, test and measurement equipment, and aerospace-grade data recording systems, serving aerospace, manufacturing, retail and healthcare markets worldwide.

Delcath Systems, Inc. is a publicly traded specialty pharmaceutical and medical device company, that develops percutaneous perfusion technologies for the targeted administration of high-dose chemotherapeutic agents to specific organs or regions of the body. Based in Queensbury, New York, the company has an intellectual property portfolio consisting of 28 patents worldwide. Delcath's Percutaneous Hepatic Perfusion (PHP) is currently undergoing Phase II and Phase III trials against tumors in th...

ALOT vs DCTH — Head-to-Head

Bigger by revenue
ALOT
ALOT
1.9× larger
ALOT
$39.2M
$20.7M
DCTH
Growing faster (revenue YoY)
DCTH
DCTH
+40.7% gap
DCTH
37.3%
-3.4%
ALOT
Higher net margin
ALOT
ALOT
10.1% more per $
ALOT
1.0%
-9.1%
DCTH
More free cash flow
DCTH
DCTH
$4.4M more FCF
DCTH
$7.7M
$3.3M
ALOT
Faster 2-yr revenue CAGR
DCTH
DCTH
Annualised
DCTH
157.0%
2.1%
ALOT

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
ALOT
ALOT
DCTH
DCTH
Revenue
$39.2M
$20.7M
Net Profit
$378.0K
$-1.9M
Gross Margin
36.2%
85.5%
Operating Margin
3.3%
-10.5%
Net Margin
1.0%
-9.1%
Revenue YoY
-3.4%
37.3%
Net Profit YoY
221.5%
44.2%
EPS (diluted)
$0.05
$-0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ALOT
ALOT
DCTH
DCTH
Q4 25
$39.2M
$20.7M
Q3 25
$36.1M
$20.6M
Q2 25
$37.7M
$24.2M
Q1 25
$19.8M
Q4 24
$40.4M
$15.1M
Q3 24
$40.5M
$11.2M
Q2 24
$33.0M
$7.8M
Q1 24
$39.6M
$3.1M
Net Profit
ALOT
ALOT
DCTH
DCTH
Q4 25
$378.0K
$-1.9M
Q3 25
$-1.2M
$830.0K
Q2 25
$-376.0K
$2.7M
Q1 25
$1.1M
Q4 24
$240.0K
$-3.4M
Q3 24
$-311.0K
$1.9M
Q2 24
$1.2M
$-13.7M
Q1 24
$2.7M
$-11.1M
Gross Margin
ALOT
ALOT
DCTH
DCTH
Q4 25
36.2%
85.5%
Q3 25
32.2%
87.2%
Q2 25
33.6%
86.3%
Q1 25
85.6%
Q4 24
33.9%
85.9%
Q3 24
35.3%
85.4%
Q2 24
36.3%
80.4%
Q1 24
31.9%
71.2%
Operating Margin
ALOT
ALOT
DCTH
DCTH
Q4 25
3.3%
-10.5%
Q3 25
-2.0%
-1.9%
Q2 25
1.5%
10.7%
Q1 25
3.2%
Q4 24
3.1%
20.1%
Q3 24
2.6%
-11.2%
Q2 24
4.1%
-50.4%
Q1 24
9.9%
-327.4%
Net Margin
ALOT
ALOT
DCTH
DCTH
Q4 25
1.0%
-9.1%
Q3 25
-3.4%
4.0%
Q2 25
-1.0%
11.2%
Q1 25
5.4%
Q4 24
0.6%
-22.5%
Q3 24
-0.8%
16.6%
Q2 24
3.6%
-176.9%
Q1 24
6.8%
-354.0%
EPS (diluted)
ALOT
ALOT
DCTH
DCTH
Q4 25
$0.05
$-0.05
Q3 25
$-0.16
$0.02
Q2 25
$-0.05
$0.07
Q1 25
$0.03
Q4 24
$0.03
$-0.06
Q3 24
$-0.04
$0.06
Q2 24
$0.15
$-0.48
Q1 24
$0.37
$-0.45

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ALOT
ALOT
DCTH
DCTH
Cash + ST InvestmentsLiquidity on hand
$3.6M
$43.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$76.9M
$111.2M
Total Assets
$140.8M
$123.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ALOT
ALOT
DCTH
DCTH
Q4 25
$3.6M
$43.5M
Q3 25
$3.9M
$41.8M
Q2 25
$5.4M
$34.4M
Q1 25
$12.8M
Q4 24
$4.4M
$32.4M
Q3 24
$4.8M
$8.3M
Q2 24
$4.0M
$14.8M
Q1 24
$4.5M
$11.8M
Total Debt
ALOT
ALOT
DCTH
DCTH
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$0
Q3 24
$2.0M
Q2 24
$4.5M
Q1 24
$7.4M
Stockholders' Equity
ALOT
ALOT
DCTH
DCTH
Q4 25
$76.9M
$111.2M
Q3 25
$75.8M
$114.8M
Q2 25
$76.6M
$105.0M
Q1 25
$80.2M
Q4 24
$92.2M
$68.7M
Q3 24
$91.8M
$8.6M
Q2 24
$91.2M
$4.2M
Q1 24
$90.3M
$14.6M
Total Assets
ALOT
ALOT
DCTH
DCTH
Q4 25
$140.8M
$123.6M
Q3 25
$143.1M
$124.3M
Q2 25
$150.3M
$116.9M
Q1 25
$87.3M
Q4 24
$166.5M
$76.6M
Q3 24
$169.0M
$31.7M
Q2 24
$126.6M
$33.9M
Q1 24
$133.3M
$36.1M
Debt / Equity
ALOT
ALOT
DCTH
DCTH
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.00×
Q3 24
0.23×
Q2 24
1.07×
Q1 24
0.50×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ALOT
ALOT
DCTH
DCTH
Operating Cash FlowLast quarter
$3.4M
$8.2M
Free Cash FlowOCF − Capex
$3.3M
$7.7M
FCF MarginFCF / Revenue
8.5%
37.1%
Capex IntensityCapex / Revenue
0.2%
2.7%
Cash ConversionOCF / Net Profit
9.05×
TTM Free Cash FlowTrailing 4 quarters
$2.9M
$21.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ALOT
ALOT
DCTH
DCTH
Q4 25
$3.4M
$8.2M
Q3 25
$249.0K
$4.8M
Q2 25
$4.4M
$7.3M
Q1 25
$2.2M
Q4 24
$-4.7M
$-1.0M
Q3 24
$162.0K
$-3.6M
Q2 24
$6.9M
$-4.5M
Q1 24
$6.5M
$-9.6M
Free Cash Flow
ALOT
ALOT
DCTH
DCTH
Q4 25
$3.3M
$7.7M
Q3 25
$202.0K
$4.3M
Q2 25
$4.3M
$6.9M
Q1 25
$2.1M
Q4 24
$-5.0M
$-1.2M
Q3 24
$-176.0K
$-3.9M
Q2 24
$6.4M
$-4.6M
Q1 24
$6.0M
$-9.6M
FCF Margin
ALOT
ALOT
DCTH
DCTH
Q4 25
8.5%
37.1%
Q3 25
0.6%
21.0%
Q2 25
11.5%
28.5%
Q1 25
10.4%
Q4 24
-12.4%
-8.2%
Q3 24
-0.4%
-34.4%
Q2 24
19.5%
-58.6%
Q1 24
15.3%
-305.7%
Capex Intensity
ALOT
ALOT
DCTH
DCTH
Q4 25
0.2%
2.7%
Q3 25
0.1%
2.2%
Q2 25
0.2%
1.6%
Q1 25
0.7%
Q4 24
0.6%
1.5%
Q3 24
0.8%
1.9%
Q2 24
1.5%
1.3%
Q1 24
1.0%
0.4%
Cash Conversion
ALOT
ALOT
DCTH
DCTH
Q4 25
9.05×
Q3 25
5.75×
Q2 25
2.70×
Q1 25
2.06×
Q4 24
-19.76×
Q3 24
-1.95×
Q2 24
5.85×
Q1 24
2.38×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ALOT
ALOT

Public Utilities Inventory Supplies$20.6M53%
Hardware Products$12.7M32%
Service And Other$5.9M15%

DCTH
DCTH

HEPZATOKIT$19.1M92%
CHEMOSAT$1.7M8%

Related Comparisons